RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 82 filers reported holding RHYTHM PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,970,025 | +23.5% | 653,000 | -11.2% | 4.87% | +68.0% |
| Q2 2023 | $12,120,150 | -7.6% | 735,000 | 0.0% | 2.90% | -26.2% |
| Q1 2023 | $13,112,400 | -38.7% | 735,000 | 0.0% | 3.93% | -47.2% |
| Q4 2022 | $21,403,200 | +7.9% | 735,000 | -9.3% | 7.44% | -9.2% |
| Q3 2022 | $19,845,000 | +1221.2% | 810,000 | +123.8% | 8.20% | +1110.6% |
| Q2 2022 | $1,502,000 | -56.1% | 362,000 | +214.8% | 0.68% | +51.5% |
| Q4 2020 | $3,419,000 | +34.8% | 115,000 | +4.1% | 0.45% | -10.2% |
| Q4 2019 | $2,537,000 | +127.9% | 110,500 | +188.5% | 0.50% | +39.9% |
| Q4 2017 | $1,113,000 | – | 38,300 | – | 0.36% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 4,909,956 | $142,977,919 | 8.04% |
| Opaleye Management Inc. | 735,000 | $21,403,200 | 7.44% |
| Frazier Life Sciences Management, L.P. | 1,894,000 | $55,153,280 | 3.43% |
| RA Capital Management | 5,516,067 | $160,627,871 | 3.26% |
| Altium Capital Management LP | 170,000 | $4,950,400 | 2.52% |
| Samsara BioCapital, LLC | 345,293 | $10,054,932 | 2.16% |
| Rock Springs Capital Management LP | 1,760,865 | $51,276,389 | 1.23% |
| Parkman Healthcare Partners LLC | 157,862 | $4,596,941 | 1.22% |
| Baker Brothers Advisors | 6,354,608 | $185,046,185 | 1.11% |
| EAM Investors, LLC | 164,695 | $4,795,918 | 0.99% |